Previous 10 | Next 10 |
Grant from the ‘ EU Joint Programme – Neurodegenerative Disease Research ’ (JPND) provides €1.45M in funding for the program AC Immune’s proprietary Morphomer™ platform continues accele...
Anti-amyloid and anti-tau drugs only slightly slow down the progression of Alzheimer's disease because misfolded amyloid and tau proteins are only two among several factors that can trigger the disease. To treat Alzheimer's disease, it is probably necessary to slow down the production...
Gainers: JinkoSolar Holding (JKS) +18%.HireQuest (HQI) +16%.American Well (AMWL) +16%.Hilltop Holdings (HTH) +13%.Daqo New Energy (DQ) +12%.Perion Network (PERI) +12%.Qutoutiao (QTT) +11%.Entercom Communications (ETM) +10%.Aerpio Pharmaceuticals (ARPO) +9%.Annexon (ANNX) +8%.Lo...
Gainers: American Well (AMWL) +17%, MediciNova (MNOV) +13%, Mallinckrodt (MNK) +7%, Capricor Therapeutics (CAPR) +8%, Adamas Pharmaceuticals (ADMS) +6%.Losers: AC Immune (ACIU) -42%, Wave Life Sciences (WVE) -34%, Rockwell Medical (RMTI)&...
Shares of the Swiss biotech AC Immune (NASDAQ: ACIU) lost over 42% of their value in pre-market trading Wednesday morning. The biotech's stock is crashing today in response to the news that its experimental Alzheimer's disease (AD) drug semorinemab failed to meet the primary endpoin...
AC Immune SA (ACIU) -43% as semorinemab flunks Alzheimer's study.Wave Life Sciences (WVE) -31% after pricing equity offering.Aurora Cannabis (ACB) -17% on soft revenue outlook.NanoVibronix (NAOV) -17% after increasing the size of the previous publi...
AC Immune SA (ACIU) craters 48% premarket in reaction to its announcement that a Phase 2 clinical trial, TAURIEL, evaluating anti-Tau antibody semorinemab in patients with early Alzheimer's disease ((AD)) failed to beat placebo as measured by the change from baseline in a scale call...
Genentech disclosed that the anti-Tau antibody did not meet the co-primary efficacy endpoint or two secondary endpoints in the TAURIEL study ; the primary safety endpoint was met Multiple other clinical stage programs progressing as planned Investigational new dr...
LAUSANNE, Switzerland, Sept. 11, 2020 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, today announced that it will showcase recent progress in its clinical programs targetin...
Substantial progress achieved across three anti-Tau clinical development programs; all clinical and preclinical programs remain on track to generate value in the second half of 2020 Top line Phase 2 data expected in the second half of 2020 for anti-Tau antibody semorinemab CHF 262.5 mill...
News, Short Squeeze, Breakout and More Instantly...
AC Immune Showcasing its Novel Morphomer-Antibody Drug Conjugate (morADC) Platform for the Treatment of Neurodegenerative Diseases at AAIC 2024 Three oral presentations at the Alzheimer’s Association International Conference (AAIC 2024), including talks on morADC, ACI-24.060,...
2024-05-30 18:30:02 ET BTIG analyst issues BUY recommendation for ACIU on May 30, 2024 04:49PM ET. ACIU was trading at $3.97 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 1 - Buy recommendations . ...
2024-05-30 18:00:07 ET Thomas Shrader from BTIG issued a price target of $8.00 for ACIU on 2024-05-30 16:49:00. The adjusted price target was set to $8.00. At the time of the announcement, ACIU was trading at $3.97. The overall price target consensus is at $10.00 with hi...